



Activity of Chitosan and Its Derivatives against *Leishmania major* and *Leishmania mexicana* In Vitro

Alaa Riezk,^a John G. Raynes,^a Vanessa Yardley,^a Sudaxshina Murdan,^b Simon L. Croft^a

^aDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom

^bDepartment of Pharmaceutics, UCL School of Pharmacy, University College London, London, United Kingdom

ABSTRACT There is an urgent need for safe, efficacious, affordable, and field-adapted drugs for the treatment of cutaneous leishmaniasis, which newly affects around 1.5 million people worldwide annually. Chitosan, a biodegradable cationic polysaccharide, has previously been reported to have antimicrobial, antileishmanial, and immunostimulatory activities. We investigated the *in vitro* activity of chitosan and several of its derivatives and showed that the pH of the culture medium plays a critical role in antileishmanial activity of chitosan against both extracellular promastigotes and intracellular amastigotes of *Leishmania major* and *Leishmania mexicana*. Chitosan and its derivatives were approximately 7 to 20 times more active at pH 6.5 than at pH 7.5, with high-molecular-weight chitosan being the most potent. High-molecular-weight chitosan stimulated the production of nitric oxide and reactive oxygen species by uninfected and *Leishmania*-infected macrophages in a time- and dose-dependent manner at pH 6.5. Despite the *in vitro* activation of bone marrow macrophages by chitosan to produce nitric oxide and reactive oxygen species, we showed that the antileishmanial activity of chitosan was not mediated by these metabolites. Finally, we showed that rhodamine-labeled chitosan is taken up by pinocytosis and accumulates in the parasitophorous vacuole of *Leishmania*-infected macrophages.

KEYWORDS cutaneous leishmaniasis, *Leishmania major*, *Leishmania mexicana*, chitosan, macrophage uptake

Leishmaniasis is an infectious disease caused by protozoan parasites belonging to the genus *Leishmania*. The parasite is transmitted between humans and mammalian reservoirs (e.g., dogs and rodents) through the bite of a female phlebotomine sand fly (1). There are two main clinical forms, cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL), with CL being the most common (2). In addition to “simple” CL, there are other complex cutaneous manifestations, including mucocutaneous leishmaniasis (MCL), diffuse cutaneous leishmaniasis (DCL), recidivans leishmaniasis (RL), and post-kala-azar dermal leishmaniasis (PKDL) (3, 4).

CL is caused mainly by *Leishmania tropica*, *Leishmania major*, and *Leishmania aethiopica* in the Old World and by *Leishmania braziliensis*, *Leishmania guyanensis*, *Leishmania mexicana*, and *Leishmania amazonensis* in the New World (5). Of the 88 countries where CL occurs, 90% of the cases are in Afghanistan, Brazil, Iran, Peru, Saudi Arabia, and Syria (1). In the mammalian host, the parasite survives and multiplies within macrophages. The cellular immune responses in CL play a critical role in the control and progress of the disease and include two main mechanisms of macrophage activation: (i) the classical pathway (M1 macrophages), in which Th1 and NK cells produce cytokines (such as gamma interferon [IFN- γ]) that stimulate the production of nitric oxide (NO) and reactive oxygen species (ROS) and the activation of other lysosomal antimicrobial activities that are responsible for killing the *Leishmania* parasites, and (ii) the alternative pathway, mediated by Th2 cytokines like interleukin-4 (IL-4) and IL-13 in

Citation Riezk A, Raynes JG, Yardley V, Murdan S, Croft SL. 2020. Activity of chitosan and its derivatives against *Leishmania major* and *Leishmania mexicana* in vitro. Antimicrob Agents Chemother 64:e01772-19. <https://doi.org/10.1128/AAC.01772-19>.

Copyright © 2020 Riezk et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Simon L. Croft, simon.croft@lshtm.ac.uk.

Received 3 September 2019

Returned for modification 10 October 2019

Accepted 8 December 2019

Accepted manuscript posted online 23 December 2019

Published 21 February 2020

the early stages of infection, forming a favorable environment for *Leishmania* proliferation (6, 7).

The pentavalent antimonial compounds sodium stibogluconate (Pentostam), and meglumine antimoniate (Glucantime) have been the standard treatment for CL for the past 70 years (8). These drugs have several limitations, including difficulty of administration, toxicity of the drug, and varying sensitivities among *Leishmania* species (9). Second-line treatments include the polyene antifungal amphotericin B, which also suffers from toxicity, the oral phospholipid miltefosine, the use of which is limited by teratogenicity, and the aminoglycoside antibiotic paromomycin (PM), which has low cure rates for certain *Leishmania* species (10–12). Treatment with intravenous liposomal amphotericin B (AmBisome) is safe and has achieved clinical success against CL at a dose of 3 mg/kg of body weight daily for 7 days (13, 14), but the high cost of this formulation limits its use (15). Two Cochrane analyses have clearly shown clinical deficiencies of most drugs (16, 17). There is an urgent need for new treatments which can eliminate the parasites and improve the healing process and are safe, reliable, and also field adaptable for use in diverse health care systems.

Chitosan is a biodegradable, biocompatible, positively charged nontoxic mucoadhesive biopolymer produced by the deacetylation of chitin. Chitosan has a pK_a of approximately 6.3 and is insoluble at alkaline pH but soluble in weak acidic solvents like acetic acid, where the amino groups become protonated. Many reports have described the antimicrobial activity of chitosan, but the actual mechanism of action has not been fully elucidated (18), although three direct mechanisms have been suggested. The first is the interaction between the protonated NH_3^+ groups of chitosan and the negatively charged cell membrane of microbes. This interaction changes the permeability of the microbial cell membrane, causing osmotic imbalances and consequently killing the microbe (18, 19). The second suggested mechanism is that chitosan binds to microbial DNA and inhibits DNA transcription, assuming that chitosan penetrates the microbial cell membrane and reaches the DNA (19, 20). The third mechanism is via chitosan's chelation of metals and binding of basic nutrients essential for microbial growth (19). An indirect mechanism of action may be related to the known proinflammatory effect of chitosan on macrophages. This involves stimulation of tumor necrosis factor alpha (TNF- α), IL-6, NO, ROS, and IFN- γ , which play critical roles in the proinflammatory response against intracellular microbes by enhancing the production of microbicidal reactive nitrogen species (21–25). Chitosan activates polymorphonuclear leukocytes, macrophages, and fibroblasts, and these properties promote wound healing (18, 26).

The poor solubility of chitosan and the loss of the cationic charge in neutral and alkaline environments are two of the major obstacles to the consideration of chitosan as a useful antimicrobial. Recently, the chemical modification of chitosan to produce various derivatives to improve its solubility and widen its application has gained attention (27, 28). Chitosan and its derivatives have been shown to have *in vitro* antileishmanial activity with 50% effective concentrations (EC_{50} s) ranging from 70 to 240 μ g/ml against *L. infantum*, *L. amazonensis*, and *Leishmania chagasi* promastigotes and amastigotes (29–34). All this makes chitosan an appropriate candidate for further studies to evaluate its suitability for the treatment of CL.

The aim of our work was to (i) determine the *in vitro* antileishmanial activity of chitosan and its derivatives against *L. major* and *L. mexicana* promastigotes and intracellular amastigotes at two different pHs (the culture medium pH of 7.5 and a lower pH of 6.5, which are both suitable for macrophage and parasite growth) (35–37), (ii) evaluate the *in vitro* role of chitosan in the activation of the macrophage M1 proinflammatory phenotype via the measurement of NO, ROS, and TNF- α production by host cells and by measuring parasite survival, and (iii) investigate chitosan uptake by macrophages to explain its activity against intracellular amastigotes.

RESULTS

***In vitro* activities of chitosan and derivatives against *L. major* and *L. mexicana*.**

The antileishmanial activities (against promastigotes and amastigotes) of high-, medium-,

TABLE 1 *In vitro* activities of chitosan and its derivatives against promastigotes at two pHs

Compound	Mean value ± SD (µg/ml) at ^a :							
	pH 7.5				pH 6.5 ^b			
	<i>L. major</i>		<i>L. mexicana</i>		<i>L. major</i>		<i>L. mexicana</i>	
	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀
Amphotericin B	0.05 ± 0.01	0.2 ± 0.02	0.14 ± 0.01	0.3 ± 0.03	0.07 ± 0.02	0.3 ± 0.1	0.13 ± 0.07	0.3 ± 0.02
HMW chitosan	105 ± 12	1,549 ± 525	140 ± 12	2,187 ± 928	5.9 ± 0.5	37 ± 9	10.4 ± 1.6	98 ± 33
MMW chitosan	113 ± 9	1,277 ± 580	150 ± 12	2,223 ± 681	6.2 ± 0.3	43 ± 8	10.9 ± 1.4	96 ± 27
LMW chitosan	118 ± 11	1,238 ± 582	157 ± 13	2,225 ± 723	6.7 ± 0.3	40 ± 8	10.2 ± 1.5	84 ± 28
Fungal chitosan	118 ± 11	1,228 ± 560	150 ± 13	1,991 ± 580	6.2 ± 0.3	42 ± 6	10.5 ± 1.3	61 ± 17
Chitosan oligosaccharide	153 ± 15	1,680 ± 506	190 ± 20	2,366 ± 461	62.5 ± 4	446 ± 92	77 ± 2.7	452 ± 36
Chitosan oligosaccharide-lactate	98 ± 9	1,226 ± 130	125 ± 14	765 ± 83	14 ± 0.1	135 ± 2	23 ± 1.4	311 ± 25
Chitosan HCl	96 ± 7	1,189 ± 211	110 ± 24	746 ± 169	13.2 ± 1	118 ± 34	20.8 ± 2.4	264 ± 61
PC1-chitosan ^c	111 ± 20	1,875 ± 230	176 ± 14	2,832 ± 412	19.9 ± 2.8	187 ± 90	32 ± 2.2	328 ± 48
PC2-chitosan ^c	104 ± 6	1,485 ± 259	170 ± 8	2,744 ± 377	16.5 ± 2.7	138 ± 49	28 ± 2.4	296 ± 53
PC3-chitosan ^c	119 ± 19	1,860 ± 365	187 ± 16	3,175 ± 580	23.3 ± 2.5	218 ± 44	37 ± 2.5	442 ± 65
Carboxymethyl chitosan	— ^d	—	—	—	—	—	—	—

^aExperiments were conducted in triplicate cultures. Experiments were reproduced a further two times with confirmed similar data (not shown). Amphotericin B deoxycholate was used as a positive control. Both RPMI alone at pH 6.5 and chitosan solvent did not show any activity against promastigotes. Statistically significant differences were found for the EC₅₀s of chitosan and its derivatives at pH 6.5 and pH 7.5 ($P < 0.05$ by using *t* test).

^b*L. major* promastigotes were significantly more susceptible to chitosan and derivatives than *L. mexicana* at pH 6.5 ($P < 0.05$ by the extra-sum-of-squares F test).

^cPhosphorylcholine-substituted chitosan (see Table 4).

^d—, no activity up to 400 µg/ml.

and low-molecular-weight (HMW, MMW, and LMW, respectively) chitosan and its derivatives (a total of 11 compounds) were tested. Dose-dependent activity (Fig. S1 and S2 in the supplemental material) against *Leishmania* promastigotes and amastigotes was observed for chitosan and its derivatives, except for carboxymethyl chitosan, which showed no activity against either parasite stage within the experimental parameters tested (pH 7.5 or 6.5 and concentrations up to 400 µg/ml). In the 72-h assays, chitosan and its derivatives (except for carboxymethyl chitosan) were 7 to 20 times more active against *L. major* and *L. mexicana* promastigotes and intracellular amastigotes (infecting peritoneal mouse macrophages [PEMs]) in culture medium at pH 6.5 than at pH 7.5 ($P < 0.05$ by *t* test) (Tables 1 and 2). HMW, MMW, and LMW chitosan, from both crustacean and fungal sources, exhibited significantly higher activities than chitosan derivatives against promastigotes and intracellular amastigotes (EC₅₀s of ≈6 µg/ml against *L. major* promastigotes and 10 µg/ml against *L. mexicana* promastigotes, and EC₅₀s of ≈12 µg/ml against *L. major* amastigotes and 16 µg/ml against *L. mexicana* amastigotes) at pH 6.5 ($P < 0.05$ by an extra-sum-of-squares F test) (Tables 1 and 2). Additionally, *L. major* promastigotes and amastigotes were significantly more sensitive to chitosan and its derivatives than *L. mexicana* promastigotes and amastigotes (approximately 1.5 to 2 times more sensitive [$P < 0.05$ by the extra-sum-of-squares F test]).

To allow like-for-like comparison, EC₅₀s were recalculated in terms of molarity, using estimated molecular weights (HMW chitosan, 342.5 kDa; MMW chitosan, 250 kDa; LMW chitosan, 120 kDa, and fungal chitosan, 130 kDa) at pH 6.5. Based on molarity (Tables S4 and S5), HMW chitosan was significantly more active against *L. major* and *L. mexicana* promastigotes and amastigotes and, hence, was used in all subsequent studies.

Host cell dependence of the antileishmanial activity of HMW chitosan at pH 6.5. We aimed to assess the host cell dependence of the antileishmanial activity of HMW chitosan and amphotericin B (Fungizone) by evaluating the *in vitro* activity against *L. major* amastigotes in three different macrophage types; the EC₅₀s and EC₉₀s in the three different macrophage populations are summarized in Table 3. There was a significant difference in the activity of HMW chitosan depending on the type of macrophage (PEMs, bone marrow-derived macrophages [BMMs], or human leukemic monocyte-like-derived cells [THP-1 cell line]) ($P < 0.05$ by the extra-sum-of-squares F test). HMW chitosan was significantly more active against intracellular amastigotes in PEMs and BMMs than in differentiated THP-1 cells.

TABLE 2 *In vitro* activities of chitosan and its derivatives against amastigotes infecting PEMs, as well as cytotoxicities toward KB cells

Compound	Mean value ± SD (µg/ml) ^a											
	Activity against amastigotes at ^b :											
	pH 7.5				pH 6.5				Cytotoxicity toward KB cells at pH 6.5 ^c			
	<i>L. major</i>		<i>L. mexicana</i>		<i>L. major</i>		<i>L. mexicana</i>		LD ₅₀		LD ₉₀	
	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀	LD ₅₀	LD ₉₀
Amphotericin B	0.07 ± 0.01	0.13 ± 0.05	0.19 ± 0.05	1.5 ± 0.2	0.06 ± 0.01	0.11 ± 0.06	0.18 ± 0.06	1.7 ± 0.3	58 ± 8	190 ± 9	58 ± 8	190 ± 9
HMW chitosan	98 ± 6	1,635 ± 245	119 ± 9	1,804 ± 304	11.4 ± 1	69 ± 18	15.4 ± 2	103 ± 28	752 ± 90	3,022 ± 366	752 ± 90	3,022 ± 366
MMW chitosan	103 ± 8	1,652 ± 287	125 ± 10	1,793 ± 323	12.9 ± 1	81 ± 18	16.3 ± 2	122 ± 34	758 ± 89	3,019 ± 400	758 ± 89	3,019 ± 400
LMW chitosan	102 ± 7	1,651 ± 282	125 ± 10	1,795 ± 320	12.1 ± 1	74 ± 14	16.1 ± 2	116.6 ± 33	803 ± 90	3,088 ± 420	803 ± 90	3,088 ± 420
Fungal chitosan	102 ± 7	1,650 ± 276	124 ± 9	1,796 ± 316	12.6 ± 3	92 ± 27	16.9 ± 2	144 ± 44	759 ± 91	3,134 ± 380	759 ± 91	3,134 ± 380
Chitosan oligosaccharide	145 ± 12	2,473 ± 500	175 ± 14	2,543 ± 505	73 ± 4	260 ± 32	86.2 ± 6	288 ± 39	765 ± 93	3,232 ± 400	765 ± 93	3,232 ± 400
Chitosan oligosaccharide-lactate	93 ± 7	1,957 ± 174	120 ± 9	2,365 ± 239	39 ± 1	201 ± 16	47 ± 2	245 ± 23	754 ± 92	3,058 ± 390	754 ± 92	3,058 ± 390
Chitosan HCl	97 ± 11	2,080 ± 516	121 ± 15	2,402 ± 667	40 ± 2	210 ± 23	47.9 ± 3	243 ± 33	781 ± 92	3,589 ± 405	781 ± 92	3,589 ± 405
PC1-chitosan ^d	144 ± 10	1,292 ± 217	169 ± 12	1,365 ± 212	68 ± 3	246 ± 26	81.7 ± 6	274 ± 38	756 ± 93	3,364 ± 398	756 ± 93	3,364 ± 398
PC2-chitosan ^d	133 ± 6	1,005 ± 194	159 ± 6	1,705 ± 170	60 ± 3	202 ± 22	71.9 ± 5	237 ± 36	800 ± 92	3,709 ± 410	800 ± 92	3,709 ± 410
PC3-chitosan ^d	163 ± 11	1,052 ± 144	187 ± 10	1,107 ± 142	71 ± 4	251 ± 30	83.5 ± 6	286 ± 41	786 ± 93	3,719 ± 378	786 ± 93	3,719 ± 378
Carboxymethyl chitosan	— ^e	—	—	—	—	—	—	—	1,184 ± 99	3,999 ± 500	1,184 ± 99	3,999 ± 500

^aExperiments were conducted in quadruplicate cultures. Experiments were reproduced a further two times with similar results (data not shown).

^bBoth RPMI alone at pH 6.5 and chitosan solvent did not show any activity against amastigotes. Statistically significant differences were found between the EC₅₀s of chitosan and its derivatives at pH 6.5 and pH 7.5 ($P < 0.05$ by using *t* test).

^cChitosan and its derivatives had low cytotoxicities toward KB cells at both pH 6.5 and 7.5, and there was no significant difference in the cytotoxicities at these two pHs ($P < 0.05$ by *t* test). No statistically significant difference was found between LD₅₀s (50% lethal dose) of the three types of chitosan and other derivatives against KB cells (except for carboxymethyl chitosan, which was the least toxic) ($P > 0.05$ by the extra-sum-of-squares *F* test).

^dPhosphoryl(choline-substituted chitosan (see Table 4).

^e—, no activity up to 400 µg/ml.

TABLE 3 HMW chitosan activities against *L. major* amastigotes in three different macrophage cultures

Host cells	Mean value \pm SD ^a			
	HMW chitosan ($\mu\text{g/ml}$)		Amphotericin B (μM)	
	EC ₅₀	EC ₉₀	EC ₅₀	EC ₉₀
PEMs	10.31 \pm 1.22	89.07 \pm 20.46	0.02 \pm 0.004	0.27 \pm 0.07
BMMs	14.60 \pm 1.79	145.7 \pm 36.2	0.04 \pm 0.005	0.43 \pm 0.1
THP-1	24.28 \pm 2.87	200.1 \pm 48.8	0.08 \pm 0.006	1.15 \pm 0.37

^aMore than 80% of macrophages were infected at 24 h for all cell lines. Cultures were grown at pH 6.5 and analyzed after 72 h. Experiment was conducted in quadruplicate cultures. Experiment was reproduced a further two times with similar results (data not shown). There were statistically significant differences in EC₅₀s between the three types of cells ($P < 0.05$ by the extra-sum-of-squares F test); chitosan and amphotericin B were significantly more active in PEMs and BMMs than in THP-1 cells. RPMI and DMEM alone at pH 6.5 and chitosan solvent did not show any activity against amastigotes.

Effects of HMW chitosan on the production of TNF- α by uninfected or *L. major*-infected BMMs at pH 6.5. The activation of M1 macrophages by Th1 lymphocytes plays an important role in the control of CL (6, 38, 39). Therefore, we measured TNF- α production by BMMs stimulated by HMW chitosan. Following exposure to HMW chitosan, the TNF- α production by BMMs was found to be dose dependent, in a bell-shaped manner, in both *Leishmania*-infected and uninfected cells, as shown in Fig. 1. After 24 h, the levels of TNF- α in the culture fluid of BMMs exposed to HMW chitosan at concentrations of 14.8, 44.4, and 133.3 $\mu\text{g/ml}$ were significantly higher than the levels in culture fluid of BMMs (infected and uninfected) that had not been exposed to chitosan, with TNF- α being the highest at 44.4 $\mu\text{g/ml}$ chitosan. Meanwhile, at other concentrations (1.64, 4.9, and 400 $\mu\text{g/ml}$), HMW chitosan did not stimulate BMMs to produce TNF- α ($P < 0.05$ by *t* test).

HMW chitosan at concentrations of 14.8, 44.4, and 133.3 $\mu\text{g/ml}$ stimulated BMMs to produce TNF- α at concentrations of 87 \pm 4.5 (mean \pm standard deviation [SD]), 712 \pm 9, and 48 \pm 3 pg/ml, respectively, in uninfected BMMs and 56 \pm 3.5, 464 \pm 10, and 32 \pm 4 pg/ml, respectively, in *L. major*-infected BMMs. Less TNF- α was generated when the chitosan concentration was increased to 133.3 $\mu\text{g/ml}$ and above. Lipopolysaccharides (LPS) from *Escherichia coli* O26:B6 (positive control) stimulated TNF- α production in both uninfected and infected BMMs after a 24-h incubation period at a




FIG 1 TNF- α production in uninfected and *L. major*-infected BMMs after 24 h of exposure to 1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g/ml}$ of chitosan at pH 6.5. The dose response in both uninfected and *L. major*-infected BMMs was bell shaped. TNF- α production was significantly decreased ($P < 0.05$ by *t* test) by infecting the cells with *L. major*. Experiment was conducted in quadruplicate, and data are expressed as mean values \pm SD. Experiment was reproduced a further two times with similar results (data not shown). Positive control was BMMs treated with LPS at 10 $\mu\text{g/ml}$. Negative control was BMMs not exposed to chitosan. Initial macrophage infection rate was $>80\%$ after 24 h. Chitosan solvent did not cause any TNF- α production.




FIG 2 ROS production in uninfected and *L. major*-infected BMMs after 4 h of exposure to 1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g/ml}$ of HMW chitosan at pH 6.5. High levels of ROS were induced by both uninfected and *L. major*-infected BMMs exposed to HMW chitosan compared to the levels in BMMs that were not exposed to chitosan ($P < 0.05$ by *t* test). Maximum production of ROS occurred at 44.4 $\mu\text{g/ml}$ of chitosan. ROS production by *L. major*-infected BMMs was significantly lower than in uninfected cells ($P < 0.05$ by *t* test). Experiment was conducted in quadruplicate, and data are expressed as mean values \pm SD. Experiment was reproduced a further two times with similar results (data not shown). Positive control was BMMs treated with 25 mM H_2O_2 (a known ROS inducer). Negative control was BMMs not exposed to chitosan. Initial macrophage infection rate was $>80\%$ after 24 h. Chitosan solvent alone did not cause any ROS production.

significantly higher level than did chitosan ($P < 0.05$ by *t* test). Our results indicated that HMW chitosan activated M1 macrophages.

Effects of HMW chitosan on the production of ROS by BMMs at pH 6.5. ROS plays an important role in the killing of intracellular amastigotes (6, 38, 39), and therefore, we measured ROS production by BMMs stimulated by HMW chitosan. HMW chitosan (at concentrations of 14.8, 44.4, and 133.3 $\mu\text{g/ml}$) increased the production of ROS (indicated by H_2DCFDA [2',7'-dichlorodihydrofluorescein diacetate] fluorescence) after 4 h of incubation but did not stimulate ROS after 8 h of incubation (Table S1). Other concentrations of HMW chitosan (1.64, 4.9, and 400 $\mu\text{g/ml}$) did not stimulate BMMs to produce ROS after 4 h or 8 h of incubation.

The ROS dose response in both uninfected and infected BMMs was bell shaped, similar to that seen with $\text{TNF-}\alpha$. Increasing the chitosan concentration from 14.8 to 44.4 $\mu\text{g/ml}$ increased ROS production, after which further increases in concentration reduced ROS production. In addition, ROS production by BMMs was significantly decreased ($P < 0.05$ by *t* test) by infecting the cells with *L. major*, as shown by the results in Fig. 2.

We found that *in vitro*, HMW chitosan had a stimulatory effect on BMM ROS production after 4 h of incubation. We therefore investigated whether this ROS plays any role in the activity of HMW chitosan against intracellular amastigotes. For these experiments, the 4-h-posttreatment time point was taken because ROS peaked at this point in BMMs in response to chitosan treatment, at a time when chitosan does not induce NO in BMMs (Table S3). Scavenging of ROS by the ROS scavenger 5 mM *N*-acetyl-L-cysteine (NAC) had no significant impact on the activity of chitosan against intracellular amastigotes ($P > 0.05$ by *t* test) (Fig. 3). The ROS scavenger caused complete scavenging of ROS production after 4 h (Table S2) and had no cytotoxicity against human squamous carcinoma cells (KB cells) or leishmanicidal activity against *L. major* amastigotes (data not shown). Even though chitosan stimulated ROS production, ROS did not play a role in the antileishmanial activity of chitosan.

Effects of HMW chitosan on the production of NO by BMMs at pH 6.5. NO plays an important role in the killing of intracellular amastigotes (6, 38, 39), and therefore, we measured NO production by BMMs stimulated by HMW chitosan. We showed that chitosan did not have a stimulatory effect on BMM NO production after 4 h of




FIG 3 Activity of HMW chitosan against *L. major* amastigotes in BMMs after 4 h, with and without ROS scavenger at pH 6.5. Infected macrophages were preincubated with 5 mM NAC for 2 h, after which HMW chitosan at a concentration of 1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g/ml}$ was added and the cells were incubated for a further 4 h. Chitosan activity against intracellular amastigotes was evaluated as described in Materials and Methods. Values are expressed as percentages of inhibition of infection relative to the results for untreated controls. After 4 h, there was no significant difference in the antileishmanial activities of chitosan after scavenging of ROS ($P > 0.05$ by *t* test). Experiment was conducted in quadruplicate, and data are expressed as mean values \pm SD. Experiment was reproduced a further two times with similar results (data not shown). Initial macrophage infection rate was $>80\%$ after 24 h.

incubation (Table S3). However, after 24 h of incubation, HMW chitosan had a stimulatory effect on BMM NO production at pH 6.5 in a clearly bell-shaped, dose-dependent manner (Fig. 4). HMW chitosan at concentrations of 14.8, 44.4, and 133.3 $\mu\text{g/ml}$ induced both uninfected and infected BMMs to produce NO (at 14.9 ± 0.3 , 34 ± 1.2 , and $11 \pm 1 \mu\text{M}$, respectively, in uninfected BMMs and 11 ± 1 , 26 ± 2.5 and $8 \pm 1.2 \mu\text{M}$, respectively, in infected BMMs), NO being highest at 44.4 $\mu\text{g/ml}$. Meanwhile, other concentrations of HMW chitosan (1.64, 4.9, and 400 $\mu\text{g/ml}$) did not stimulate BMMs to produce NO after 24 h of incubation.

LPS caused significantly higher NO production than did HMW chitosan ($P < 0.05$ by *t* test) in both uninfected and infected BMMs. The levels of NO produced by *L. major*-infected BMMs exposed to LPS (positive control) or HMW chitosan were significantly lower than the levels produced by uninfected BMMs ($P < 0.05$ by *t* test) (Fig. 4).




FIG 4 NO production in uninfected and *L. major*-infected BMMs after 24 h of exposure to 1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g/ml}$ of chitosan at pH 6.5. The response in both uninfected and infected BMMs was bell shaped and related to chitosan concentration. Maximal production of NO was stimulated by 44.4 $\mu\text{g/ml}$ of chitosan. NO production was significantly decreased ($P < 0.05$ by *t* test) when the cells had been infected with *L. major*. Experiment was conducted in quadruplicate cultures, and data are expressed as mean values \pm SD. Experiment was reproduced a further two times with similar results (data not shown). Positive control was BMMs treated with 10 $\mu\text{g/ml}$ LPS. Negative control was BMMs not exposed to chitosan. Initial macrophage infection rate was $>80\%$ after 24 h. Chitosan solvent alone did not cause any NO production.




FIG 5 Activity of HMW chitosan against *L. major*-infected BMMs after 24 h in the presence or absence of an NO inhibitor at pH 6.5. Infected macrophages were preincubated with the NO inhibitor L-NMMA (0.4 mM) for 2 h, following which HMW chitosan at a concentration of 1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g}/\text{ml}$ was added and the cells were incubated for a further 24 h. Chitosan activity against intracellular amastigotes was evaluated as described in Materials and Methods. Values are expressed as percentages of inhibition relative to the results for untreated controls. After 24 h, there was no significant difference in the activity of chitosan after inhibition of NO ($P > 0.05$ by *t* test). Experiment was conducted in quadruplicate cultures, and data are expressed as mean values \pm SD. Experiment was reproduced a further two times and the results were confirmed (data not shown). Initial macrophage infection rate was $>80\%$ after 24 h.

As HMW chitosan had an *in vitro* stimulatory effect on BMM NO production after 24 h of incubation, we investigated further whether NO has any role in the activity of HMW chitosan against intracellular amastigotes. Inhibition of NO production by the NO inhibitor N^G-methyl-L-arginine acetate salt (L-NMMA) at 0.4 mM had no significant influence on the activity of chitosan against intracellular amastigotes ($P > 0.05$ by *t* test) (Fig. 5), although the NO inhibitor did cause a complete inhibition of NO production (Table S2) after 24 h and had no cytotoxic effects against KB cells and no leishmanicidal activity against intracellular *L. major* amastigotes (data not shown). Even though chitosan stimulated NO production, it did not play a role in the antileishmanial activity of chitosan.

Cellular uptake of HMW chitosan and inhibition of endocytosis. We found that the activation of M1 macrophages by HMW chitosan did not play a role in its activity against intracellular amastigotes. Therefore, we investigated whether the antileishmanial effects of HMW chitosan against intracellular amastigotes after 4 h and 24 h of exposure were dependent on the direct activity of chitosan following its entry into the macrophages at pH 6.5. No significant difference was observed in the activity of chitosan against intracellular amastigotes when it was added after prior phagocytosis inhibition with cytochalasin D ($P > 0.05$ by *t* test) (Fig. 6). In contrast, dynasore, an inhibitor of pinocytosis (clathrin-mediated endocytosis [CME]), did significantly affect chitosan-mediated parasite killing at pH 6.5 ($P < 0.05$ by *t* test) (Fig. 6). The same activity was seen at pH 7.5 (Fig. 6C). The two inhibitors had no cytotoxicity against KB cells or activity against intracellular *L. major* amastigotes at the concentrations used. Pinocytosis (CME) played a critical role in the efficacy of HMW chitosan against intracellular amastigotes.

Fluorescence microscopy of the uptake of chitosan by macrophages. Rhodamine-labeled chitosan was used to track the delivery of chitosan to the parasitophorous vacuoles (PVs) of *Leishmania*-infected macrophages. Fig. 7 illustrates the cellular uptake of chitosan by BMMs infected with green fluorescent protein (GFP)-labeled *L. major* (*L. major*-GFP) or *L. mexicana*-GFP after 4 h and 24 h of exposure to rhodamine-labeled chitosan. There was colocalization of chitosan and intracellular amastigotes after 4 h and 24 h, with normalized mean deviation product (nMDP) color indexes of 0.7 and 1, respectively (see "Microscopic imaging of the cellular uptake of rhodamine-labeled chitosan" in Materials and Methods). The uptake of chitosan increased in a time-dependent manner. The results in Fig. 7XA and XB, panels D and E, show this uptake after 4 h and 24 h, respectively, as well as the accumulation of chitosan in PVs (Fig. 7,




FIG 6 Activities of HMW chitosan against *L. major*-infected BMMs after 4 h at pH 6.5 (A), 24 h at pH 6.5 (B), or 24 h at pH 7.5 (C), with or without phagocytosis inhibitor or pinocytosis (CME) inhibitor. We found that chitosan requires pinocytosis (CME) and not phagocytosis by BMMs for killing of *L. major* amastigotes at pH 6.5 and 7.5. BMMs were infected with stationary-phase promastigotes. Some of the infected macrophages were preincubated with cytochalasin D (phagocytosis inhibitor) or dynasore (pinocytosis [CME] inhibitor) and exposed to various concentrations (1.64, 4.9, 14.8, 44.4, 133.3, or 400 $\mu\text{g/ml}$) of chitosan for 4 h and 24 h, followed by microscopic counting of the number of infected macrophages. There was no significant difference in the activities of HMW chitosan after inhibition of phagocytosis ($P > 0.05$ by *t* test). In contrast, significant inhibition of chitosan-mediated parasite killing occurred in the presence of dynasore at the two pH values ($P < 0.05$ by *t* test). Values are expressed as percentages of inhibition of infection relative to the results for untreated controls. Experiments were conducted in quadruplicate cultures, and data are expressed as mean values \pm SD. Experiments were reproduced a further two times and the results confirmed (data not shown). Initial macrophage infection rate was $>80\%$ after 24 h.

colocalization of rhodamine and GFP shown by yellow color). The results in Fig. 7XA and XB, panels F, also show that the inhibition of pinocytosis (CME) with dynasore prevented the uptake of chitosan, with a negative nMDP color index that represents no colocalization of chitosan and amastigotes. This is also supporting evidence for the uptake by pinocytosis as seen by the results in Fig. 6.

DISCUSSION

The literature on the antileishmanial activity of chitosan and its derivatives is limited, especially pertaining to its mechanism(s) of action (19, 40, 41). In this study, we assessed the antileishmanial activity of various forms of chitosan, including low-, medium-, and high-molecular-weight chitosan and chitosan derivatives. Chitosan derivatives are generally produced by chemical modification of the amino or hydroxyl groups of chitosan for the optimization of the physicochemical properties. We found that chitosan and its derivatives had minimal cytotoxicity against KB cells, with 50% lethal doses (LD_{50} s) of




FIG 7 Fluorescence microscopy images of the cellular uptake of rhodamine-labeled chitosan at 4 h and 24 h at pH 6.5 by BMMs infected with *L. major*-GFP (XA) or with *L. mexicana*-GFP (XB). Blue represents the nuclei of BMMs, green represents intracellular amastigotes, red represents labeled chitosan, and yellow represents merged red chitosan and green *Leishmania* parasites. (A to F) Infected BMMs unexposed to chitosan after 4 h (A) or 24 h (B), exposed to chitosan after 4 h (D) or 24 h (E), unexposed to chitosan after 24 h (C), and exposed to chitosan and pinocytosis inhibitor (dynasore) after 24 h (F).

$\geq 750 \mu\text{g/ml}$ in RPMI 1640 at pH 7.5 or 6.5. These data support previous reports of chitosan's low cytotoxicity against CCRF-CEM (human lymphoblastic leukemia) and L132 (human embryonic lung) cells that had similar LD_{50} s (42, 43).

We determined that a lower pH of 6.5 enhanced the antileishmanial activities of chitosan and its derivatives against *L. major* and *L. mexicana* promastigotes and amastigotes by 7 to 20 times compared to the results at pH 7.5. This higher activity of chitosan at the lower pH of 6.5 could be due to its greater ionization (protonation of the amino groups; the pK_a of chitosan is ≈ 6.3). The greater positive charge could increase the antimicrobial activity of chitosan due to interaction with the negatively charged microbial membrane (in accordance with the first postulated mechanism of antimicrobial activity described in the introduction) (18, 19). A higher chitosan activity at lower pH (pH ≈ 5) has previously been reported against *Escherichia coli* and *Salmonella enterica* serovar Typhimurium (44, 45).

Our study is the first to show the pH dependence of the antileishmanial activity of chitosan and its derivatives and could explain why reports of the antileishmanial activity of chitosan in the literature have shown such variability, with EC_{50} s ranging from 70 to 240 $\mu\text{g/ml}$ against *L. infantum*, *L. amazonensis*, and *L. chagasi* promastigotes and amastigotes (29–34). For example, in one study, the EC_{50} of chitosan against *L. infantum* amastigotes (in PEMs) in RPMI 1640 medium was 100.81 $\mu\text{g/ml}$, but the pH at which the experiment was conducted was not mentioned (29). The influence of pH was also seen when the antileishmanial activities of chitosan (of the different molecular weights) and chitosan derivatives were compared. While the different chitosans and derivatives showed minor differences in their antileishmanial activities at pH 7.5, the derivatives were 3 to 5 times less active than the HMW, MMW, LMW, and fungal chitosan at the lower pH of 6.5. This reduced activity could be due to the smaller number of amino groups on the chitosan derivatives (see Fig. 8). These derivatives are more soluble at a higher pH and have activities similar to those of chitosan, but at a




FIG 8 The structures of chitosan (60) and its derivatives, chitosan HCl, carboxymethyl chitosan (61), chitosan oligosaccharide (60), PC-chitosan (republished from reference 28 with permission of the publisher), and chitosan oligosaccharide lactate (59).

lower pH, the higher protonation of the chitosan improves the antileishmanial activity significantly (46, 47). Carboxymethyl chitosan had no antileishmanial activity—most of the amino groups on this derivative have been replaced by carboxymethyl moieties, making the molecule negatively charged (48).

The higher antileishmanial activity of HMW chitosan compared to the activities of MMW and LMW chitosan mirrors its greater antibacterial activity in another study against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (49). HMW has a long chain and, therefore, more glucosamine units and possesses more amino groups (Fig. 8), resulting in more protonated groups (-NH_3^+) than MMW and LMW chitosan have (49), which could explain its greater potency.

We also showed that the antileishmanial activity of chitosan is significantly greater against *L. major*-infected PEMs or BMMs than against *L. major*-infected differentiated THP-1 cells, in the order PEMs > BMMs > THP-1 cells, underlining the need to take the host cell into consideration when conducting similar experiments (50).

In order to understand the potential anti-amastigote mechanism(s) of chitosan, we investigated whether the activity of HMW chitosan against the intracellular amastigotes was via direct uptake into the host cell and localization in the parasitophorous vacuole or indirectly via the activation of M1 macrophages, given that the cellular immune responses in cutaneous leishmaniasis play a critical role in self-cure (51, 52).

The activation of M1 macrophages by the Th1 lymphocyte subpopulation, which produces different cytokines, primarily $\text{IFN-}\gamma$ and $\text{TNF-}\alpha$, is crucial for the killing of

intracellular *Leishmania* via the triggering of an oxidative burst, and therefore, the host cells increase the production of ROS and NO, which are responsible for killing of the parasite (38, 39). We found that HMW chitosan stimulated TNF- α production by macrophages, and this would be expected to be an indicator of an M1 macrophage that would have greater leishmanicidal activity. Our results show that chitosan stimulated BMM ROS production with a peak after 4 h and led to significant increases in the TNF- α and NO production after 24 h in a bell-shaped response. Similar findings have been reported showing that HMW chitosan had an *in vitro* stimulatory effect on NO production in PEMs (from male rats) (25) and LMW chitosan stimulated RAW264.7 macrophage TNF- α production (24). Another study demonstrated that LMW chitosan induced ROS production in an epithelial, human breast cancer cell line (53). The bell-shaped responses are consistent with a study that showed that chitosan stimulated NO and TNF- α production in peritoneal macrophages in a dose-dependent manner and that their levels tended to decrease at higher concentrations of chitosan (320 μ g/ml) (54). This type of response has also been reported previously for tucareol for both its immunomodulatory activity and activity against experimental *Leishmania donovani* infections, albeit at lower doses (55). Despite the observed chitosan-induced ROS and NO production, there was no evidence that this contributed to the antileishmanial activity in our study: the inhibitors that we used to suppress their production had no effect on the ability of chitosan to kill intracellular *Leishmania* amastigotes (Fig. 3 and 5). This led us to investigate the cellular uptake of HMW chitosan and its relationship to the antileishmanial activity.

The uptake of the large charged molecule of HMW chitosan has not been systematically studied before, and there is no clear evidence of its penetration of cell membranes or of its uptake mechanism. Macrophages are known to take up extracellular materials and plasma by endocytosis. Endocytosis mainly occurs via two different cellular uptake mechanisms, pinocytosis and phagocytosis, where pinocytosis is fluid-phase endocytosis and phagocytosis is the process of engulfing large particles (56). Inhibition of pinocytosis (clathrin-mediated endocytosis [CME]) significantly reduced the antileishmanial activity of HMW chitosan. Therefore, in our study, pinocytosis (CME) was considered to be the main mechanism for the uptake of HMW chitosan by BMMs, indicating a direct antileishmanial effect of this molecule against amastigotes. Other studies have previously reported pinocytosis as the pathway for the uptake of chitosan of different molecular weights by HEK293 epithelial cells (57). The results of fluorescence imaging in our study showed that in BMMs, HMW chitosan is taken up into the parasitophorous vacuole (PV) where the *Leishmania* parasites reside, with the labeled chitosan being internalized within 4 h and increasing up to 24 h later. This is consistent with another study where rhodamine isothiocyanate-chitosan (molecular weight of 113 kDa was labelled with RITC) was found to be delivered directly to the U937 macrophage lysosome after 24 h (58). The accumulation of chitosan in the PV might be due to chitosan's relatively high pK_a of 6.3 making it more soluble and protonated in the acidic contents of the vacuole. This is consistent with the results of a study using bafilomycin to inhibit acidification and prevent chitosan accumulation within macrophages (58).

In summary, our studies indicate that chitosan and its water-soluble derivatives showed antileishmanial activity against both *L. major* and *L. mexicana* promastigotes and amastigotes in a pH-dependent manner. At pH 6.5, HMW chitosan is more active than MMW and LMW chitosan and chitosan derivatives, in particular those where the amino groups are replaced. In addition, HMW chitosan activated M1 macrophages, stimulating them to produce NO and ROS. However, the antileishmanial activity of chitosan was not due to such immune activation, as an NO inhibitor and an ROS scavenger failed to reduce the antileishmanial activity. Instead, the antileishmanial activity was related to direct uptake of chitosan into the parasitophorous vacuole by pinocytosis (CME). HMW chitosan demonstrated effective *in vitro* antileishmanial activity with minimal cytotoxicity, and future work will focus on *in vivo* studies, formulations, and routes of administration.

TABLE 4 Details of chitosan and its derivatives used in the study

Compound (source)	Chitosan mol wt (kDa unless otherwise specified); further description	Supplier
HMW (crustacean shells)	310–375	Sigma, UK
MMW (crustacean shells)	190–310	Sigma, UK
LMW (crustacean shells)	50–190	Sigma, UK
Fungal chitosan (white mushroom)	110–150	S. Somavarapu
Chitosan oligosaccharide	≤5 Da	S. Somavarapu
Chitosan oligosaccharide-lactate	Avg Mn 5; oligosaccharide, 60%	S. Somavarapu
Chitosan-HCl	47–65	S. Somavarapu
Carboxymethyl chitosan	543.519 Da; level of substitution, 95%	S. Somavarapu
PC1-chitosan ^a	33; PC mol%, 30	F. Winnik
PC2-chitosan ^a	108; PC mol%, 20	F. Winnik
PC3-chitosan ^a	109; PC mol%, 30	F. Winnik

^aPhosphorylcholine-substituted chitosan.

MATERIALS AND METHODS

Drugs and chemicals. Stocks of amphotericin B deoxycholate (5.2 mM [aqueous]) (Fungizone; Gibco, UK) were prepared, aliquoted, and kept at -20°C until use. Chitosan with three different molecular weights and its derivatives were used and are summarized in Table 4 and Fig. 8 (28, 59, 60, 61). Solutions of chitosan and derivatives were prepared by dissolving 1 g in 100 ml of 1% (vol/vol) acetic acid solution at room temperature with continuous stirring for 24 h until a clear solution was obtained. The pH of the solution was adjusted to approximately 6 by adding sodium hydroxide 2N (NaOH; Sigma, UK) solution and monitoring with a pH meter (Orion model 420A). The chitosan solutions were autoclaved (121°C for 15 min). Phosphorylcholine (PC)-substituted chitosan generated through reductive amination of PC-glyceraldehyde with primary amines of deacetylated chitosan (57 kDa) was kindly provided by F. Winnik (Montreal University, Canada). The percentages of substitution were controlled and determined by nuclear magnetic resonance (NMR) spectroscopy (28). Chitosan's pK_a is approximately 6.3, and therefore, the approximate degrees of ionization of chitosan are 61% and 6% at pH 6.5 and 7.5, respectively.

Ethics statement. All animal work was carried out under a UK Home Office project license according to the Animal (Scientific Procedures) Act 1986 and the new European Directive 2010/63/EU. The project license (70/8427) has been reviewed by the LSHTM Animal Welfare and Ethical Review Board prior to submission and consequent approval by the UK Home Office.

Cell lines. Peritoneal mouse macrophages (PEMs) were obtained from 8- to 12-week-old female CD-1 mice (Charles River Ltd., UK). Two milliliters of a 2% (wt/vol) starch solution in phosphate-buffered saline (PBS; Sigma, UK) was injected intraperitoneally. After 24 h, the animal was sacrificed and the PEMs were harvested by peritoneal lavage with cold RPMI 1640 medium (Sigma, UK) containing 200 units penicillin and 0.2 mg streptomycin per milliliter (PenStrep; Sigma, UK). Subsequently, PEMs were centrifuged at $450 \times g$ at 4°C for 15 min, and then the pellet was resuspended in RPMI 1640 with 10% (vol/vol) heat-inactivated fetal calf serum (HIFCS; Gibco, UK).

Bone marrow-derived macrophages (BMMs) were obtained from femurs of 8- to 12-week-old female BALB/c mice (Charles River Ltd.). Briefly, the bone marrow cells were carefully flushed from the bone with Dulbecco's modified Eagle's medium (DMEM; Thermofisher, UK) with 10% (vol/vol) HIFCS, 100 U/ml penicillin, and 100 mg/ml streptomycin (Sigma, UK). Cells were pelleted by centrifugation ($450 \times g$ for 10 min) and resuspended in 10 ml DMEM with 10% (vol/vol) HIFCS and 50 ng/ml human macrophage colony-stimulating factor (HM-CSF; Thermofisher, UK). After plating out in T175 flasks (Greiner Bio-One, Stonehouse, UK), BMMs were kept at 37°C , 5% CO_2 for 7 to 10 days, after which they were harvested, counted, and used.

THP-1 cells are a human leukemic monocyte-like-derived cell line. THP-1 cells were cultured in RPMI 1640 medium supplemented with L-glutamine and 10% HIFCS. THP-1 cells were incubated in RPMI 1640 plus 10% (vol/vol) HIFCS and 20 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma, UK) at 37°C and 5% CO_2 for 72 h to induce maturation transformation of these monocytes into adherent macrophages (50).

Human squamous carcinoma (KB) cells are adherent cells derived from epidermal carcinoma in the mouth. KB cells were cultured in RPMI 1640 medium with 10% HIFCS.

The numbers of cells and macrophages were estimated by counting with a Neubauer hemocytometer by light microscopy ($\times 400$ total magnification).

Parasites. Four *Leishmania* strains were used, two of which (*L. major* [MHOM/SU/73/SASKH] and *L. mexicana* [MNYC/BZ/62/M379], kindly donated by G. Getti [University of Greenwich, UK]) were GFP labeled for the fluorescence microscopy study. They were cultured in Schneider's insect medium (Sigma, UK) with 23% (vol/vol) HIFCS, $1 \times$ penicillin-streptomycin-glutamine (Gibco-Invitrogen) and supplemented with 700 $\mu\text{g}/\text{ml}$ G418 (an aminoglycoside antibiotic; Sigma, UK). *L. major* (MHOM/SA/85/JISH118) and *L. mexicana* (MNYC/BZ/62/M379) were used for other experiments without the G418. Promastigotes were incubated at 26°C , and the maximum passage number used was 7.

In vitro cytotoxicity assays. Resuspended KB cells ($4 \times 10^4/100 \mu\text{l}$) were allowed to adhere to the bottom of a 96-well plate overnight and then exposed to specific concentrations of the tested compounds for 72 h at 37°C and 5% CO_2 in an incubator. Podophyllotoxin (Sigma, UK) was included as a

positive control at a starting concentration of 0.05 μ M. Cytotoxicity was evaluated by a cell viability assay using resazurin sodium salt solution (Sigma, UK), which was prepared according to the manufacturer's instructions. Twenty microliters of the resazurin solution was added to each well of the plates, and fluorescence (cell viability) (62) was measured over a period of 1 to 24 h using a SpectraMax M3 plate reader (excitation/emission at 530/580 nm and 550-nm cutoff). Results were expressed as follows: percentage of inhibition = $(100 - x)\%$ viability (mean \pm standard deviation [SD] σ). Cytotoxicity was evaluated in RPMI 1640 at two pHs (at the normal pH of RPMI, pH 7.5, and at a lower pH of 6.5). The pH of RPMI 1640 was reduced from 7.5 to 6.5 by adding 0.05 M acidic buffer 2-*N*-morpholino ethanesulfonic acid (MES; Sigma, UK). RPMI 1640 plus MES (0.05 M) at pH 6.5 did not show any cytotoxicity to KB cells.

In vitro 72-h activity of chitosan and its derivatives against extracellular *L. major* and *L. mexicana* promastigotes. Promastigotes in RPMI 1640 medium were tested while in the exponential growth phase. The promastigotes were diluted to a density of 5×10^6 promastigotes/ml and then exposed to different concentrations of HMW, MMW, and LMW chitosan, chitosan derivatives, and amphotericin B (positive control) in sterile 96-well flat-bottom culture plates for 72 h at 26°C. The activity of the compounds against promastigotes was evaluated using the resazurin sodium salt solution (Sigma, UK) as described above. pH plays a critical role in the solubility and protonation of chitosan, so the activity against promastigotes was evaluated at two different pHs (pH 7.5 and a lower pH of 6.5 obtained by adding MES). The results were expressed as follows: percentage of inhibition = $100\% - x\%$ viability (mean \pm SD).

In vitro 72-h activity of chitosan and its derivatives against intracellular amastigotes of *L. major* and *L. mexicana*. One hundred microliters of PEM culture at 4×10^5 cells/ml was dispensed into each well of a 16-well LabTek tissue culture slide (Thermo Fisher, UK) at pH 7.5 or pH 6.5 and incubated for 24 h at 37°C in 5% CO₂. After 24 h, the wells were washed with fresh culture medium to remove nonadherent cells. Stationary-phase, low-passage-number *Leishmania* promastigotes were then added to PEMs at a ratio of 5:1. This infection ratio was previously found to give sufficiently high and reproducible infection levels. Slides were incubated for another 24 h at 34°C to mimic dermal temperatures in 5% CO₂. Any free, extracellular parasites were removed by washing the wells with cold culture medium. One slide was fixed with 100% methanol for 2 min and stained with 10% Giemsa stain for 5 min. The number of PEMs infected with *Leishmania* amastigotes per 100 macrophages was counted under a microscope. All the experiments were conducted at macrophage infection levels of above 80% prior to the addition of chitosan. Chitosan, its derivatives, and amphotericin B solutions at a range of concentrations (in quadruplicate) were added to the wells (100 μ l), and the slides were incubated for 72 h at 34°C in 5% CO₂. After 72 h, the slides were fixed with 100% methanol for 2 min and stained with 10% Giemsa stain for 5 min. The slides were examined, and the percentages of macrophages infected were determined. The antileishmanial activities of compounds were expressed as the percentages of reduction in infected macrophages compared to the numbers of infected macrophages in untreated control wells (63). RPMI 1640 plus MES (0.05 M) at pH 6.5 had no activity against *Leishmania* amastigotes.

Influence of the origin of the host cell on the in vitro activity of HMW chitosan against *L. major* amastigotes. A further two host cell types, THP-1 and BMMs, were infected with *Leishmania major* and the activity of HMW chitosan was assessed. THP-1 cells (cultured in RPMI 1640 plus 10% HIFCS) and BMMs (cultured in DMEM plus 10% HIFCS) were used to assess the host cell dependence of the antileishmanial activity of HMW chitosan (50). The experiment was conducted as described above for the assay of chitosan activity against intracellular amastigotes of *L. major* and *L. mexicana* at pH 6.5.

The role of HMW chitosan in BMM activation. We chose BMMs to evaluate the activation effects of HMW chitosan and to study the cell uptake of chitosan as this macrophage population is more homogenous than those of PEMs and THP-1 cells (64); both PEMs and BMMs have been reported to have similar acidic pHs of ≈ 5.5 in parasitophorous vacuoles of *L. amazonensis*-infected cells (65–67). One hundred microliters of BMMs (4×10^5 /ml) in DMEM at pH 6.5 was dispensed into each well of 96-well plates (standard clear plates for nitric oxide assay and black-wall, clear-bottom plates for ROS and TNF- α assay) and incubated for 24 h at 37°C in 5% CO₂. Plates were washed with DMEM to remove nonadherent macrophages. *L. major* at a 1:5 ratio (5 parasites per host cell) was then added to the wells, and the plates were incubated for 24 h at 34°C in 5% CO₂ to allow infection of the adherent macrophages. After 24 h of incubation with macrophages, the infection rate was more than 80%. The effects of HMW chitosan on BMM activation at pH 6.5 were determined by quantifying the release of TNF- α , ROS, and NO as described below.

(i) Measurement of TNF- α . HMW chitosan at concentrations of 1.64, 4.9, 14.8, 44.4, 133.3, and 400 μ g/ml was added to infected and uninfected macrophages (see "Uptake of chitosan by macrophages" above), and the plates were incubated for 4 or 24 h at 34°C in 5% CO₂. Lipopolysaccharides from *Escherichia coli* O26:B6 (LPS, 100 ng/ml; Sigma, UK) were used as a positive control and inducer. TNF- α release by the BMMs was measured using a mouse TNF- α enzyme-linked immunosorbent assay (ELISA) kit (product number ab208348; abcam, UK) according to the manufacturer's instructions, using a SpectraMax M3 microplate reader (wavelength 450 nm).

(ii) Measurement of ROS. ROS was measured using a 2',7'-dichlorofluorescein diacetate (DCFDA) cellular reactive oxygen species detection kit (abcam, UK). Uninfected and infected macrophages were treated with 25 μ M DCFDA in PBS for 45 min at 37°C and then washed once in the buffer. The cells were cultured at 34°C in 5% CO₂ for 0.5, 1, 2, 4, 8, and 24 h, with 1.64, 4.9, 14.8, 44.4, 133.3, and 400 μ g/ml of HMW chitosan or in the presence of H₂O₂ (25 mM) (Thermofisher, UK) as a positive control, in DMEM plus 10% HIFCS (pH 6.5) in quadruplicate wells. In some experiments, cells were pretreated with a selective inhibitor of ROS, *N*-acetyl-L-cysteine (NAC) (5 mM; Sigma, UK) for 2 h before the addition of the

inducer or chitosan. At 0.5, 1, 2, 4, 8, and 24 h, the plates were read, using a SpectraMax M3 microplate reader (excitation/emission at 485/535 nm).

(iii) Measurement of NO. NO was measured using Griess reagent (ThermoFisher, UK). HMW chitosan at concentrations of 1.64, 4.9, 14.8, 44.4, 133.3, and 400 $\mu\text{g/ml}$ was added to infected and uninfected macrophages, and the plates were incubated at 34°C in 5% CO_2 for 4 and 24 h. LPS (100 ng/ml) was used as a positive control. In some experiments, cells were pretreated with the selective inhibitor of nitric oxide N^G -methyl-L-arginine acetate salt (L-NMMA) (0.4 mM; Sigma, UK) for 2 h before the addition of LPS. NO was quantified according to the kit protocol. Briefly, 150 μl of the cell culture supernatants (particulates were removed by centrifugation) was mixed gently with 150 μl of the Griess reagent in a 96-well plate and the mixture was incubated for 30 min at room temperature. The absorbance was measured using a SpectraMax M3 plate reader (wavelength 548 nm). Sodium nitrite (Sigma, UK) at different concentrations was used to create a standard curve (68).

Uptake of chitosan by macrophages. The uptake of HMW chitosan was evaluated using two methods. The first method used two endocytosis inhibitors: cytochalasin D (1 $\mu\text{g/ml}$; Sigma, UK), which is a phagocytosis inhibitor, and dynasore (30 $\mu\text{g/ml}$; Sigma, UK), which inhibits pinocytosis (clathrin-mediated endocytosis [CME]) by blocking the GTPase activity of dynamin (69–71). The second method used dynasore and rhodamine-labeled chitosan (200 kDa; Creative PEGWorks, USA) to track cellular uptake of chitosan over time by fluorescence microscopy.

(i) Activity of chitosan after inhibition of the endocytic pathway of BMMs. One hundred microliters of BMM culture ($4 \times 10^5/\text{ml}$) in DMEM at pH 6.5 or pH 7.5 was dispensed into each well of 16-well LabTek culture slides and infected with stationary-phase *L. major* promastigotes. Some of the infected BMMs were pretreated with dynasore (30 $\mu\text{g/ml}$) or cytochalasin D (1 $\mu\text{g/ml}$) for 2 h. Subsequently, HMW chitosan was added to each well at concentrations of 1.64, 4.9, 14.8, 44.4, 133.3, and 400 $\mu\text{g/ml}$ and macrophages were incubated for 4 or 24 h at 34°C in 5% CO_2 . After each time point, the slides were examined as described above for the assay of chitosan activity against intracellular amastigotes of *L. major* and *L. mexicana*. The inhibition activity of the uptake (phagocytosis or pinocytosis) of the two inhibitors was evaluated on a fluorescence plate reader using fluorescent latex beads and pHrodo red dextran (72). We showed that cytochalasin caused 94 and 84% inhibition of phagocytosis of fluorescent latex beads (Sigma-Aldrich, UK) after 4 h and 24 h, respectively, and dynasore caused 95 and 90% inhibition of pinocytosis of pHrodo red dextran ($M_w = 10,000$; Thermo Fisher, UK) after 4 h and 24 h, respectively (Table S6 in the supplemental material).

(ii) Microscopic imaging of the cellular uptake of rhodamine-labeled chitosan. The qualitative characterization of chitosan uptake of cells was carried out by wide-field microscopy (Nikon Ti-E inverted microscope). Briefly, after deriving BMMs, 500 μl of the BMMs (in DMEM plus 10% HIFCS at pH 6.5, 4×10^4 macrophages per ml) was seeded in each well of a 4-well LabTek tissue culture slide (Thermo Fisher, UK) and incubated for 24 h at 37°C in 5% CO_2 . Subsequently, 5 $\mu\text{g/ml}$ of the nuclear dye Hoechst 33342 (excitation/emission at 350/461 nm; ThermoFisher, UK) was added and the slides were incubated for 30 min at 37°C in 5% CO_2 . The macrophages were washed with PBS, and then *L. major*-GFP or *L. mexicana*-GFP parasites were added at a ratio of 10:1 and further incubated for 24 h at 34°C in 5% CO_2 (we used a 10:1 ratio, not 5:1 as described above, as in this experiment, different strains of *L. major*-GFP and *L. mexicana*-GFP were used and the ratio 10:1 was sufficient to obtain a high infection rate). Macrophages were then washed with PBS and 500 μl of LysoTracker deep red (50 nM, excitation/emission at 647/668 nm; Thermo Fisher, UK) was added to each well. The labeled, infected macrophages were then exposed to 30 $\mu\text{g/ml}$ rhodamine-labeled chitosan (200 kDa; Creative PEGWorks, USA) in 500 μl of fresh DMEM plus 10% HIFCS, pH 6.5, and incubated for 4 and 24 h at 37°C with live imaging at each time point. In some experiments, infected BMMs were preincubated with dynasore 30 $\mu\text{g/ml}$ for 2 h before adding rhodamine-labeled chitosan. All the images were collected using a Nikon Ti-E inverted microscope equipped with a 63 \times objective using Nikon Elements software. Three images for each experiment were then analyzed using ImageJ software. The degree of correlation between pixels in the red and green channels was assessed by using the Colocalization Colormap plugin in the ImageJ software. This plugin enables quantitative visualization of colocalization by calculating the normalized mean deviation product (nMDP) in a color nMDP scale (from -1 to 1): negative indexes (cold colors) refer to no colocalization, while indexes of more than 0 (hot colors) display colocalization and higher numbers refer to greater colocalization (73, 74).

Statistical analysis. Dose-response curves and EC_{50} s were calculated using GraphPad Prism version 7.02 software, and the corresponding sigmoidal dose-response curves were established by using a nonlinear fit with variable slope models. Results are given as mean values \pm SD. EC_{50} s were compared by using extra-sum-of-squares F tests. The *t* test was used to compare differences between means of two or more groups, and *P* values of 0.05 were considered statistically significant.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.8 MB.

ACKNOWLEDGMENTS

Alaa Riezk's doctoral project received funding from the London School of Hygiene and Tropical Medicine (LSHTM) and the Council for At-Risk Academics (CARA, UK).

We are grateful to S. Somavarapu (UCL School of Pharmacy) and K. Van Bocxlaer (University of York) for supply of chemicals and helpful discussions. The authors

acknowledge the facilities and the scientific and technical assistance of the LSHTM Wolfson Cell Biology Facility, with specific thanks to E. McCarthy.

REFERENCES

- Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S. 2007. Cutaneous leishmaniasis. *Lancet Infect Dis* 7:581–596. [https://doi.org/10.1016/S1473-3099\(07\)70209-8](https://doi.org/10.1016/S1473-3099(07)70209-8).
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* 7:e35671. <https://doi.org/10.1371/journal.pone.0035671>.
- Croft SL, Sundar S, Fairlamb AH. 2006. Drug resistance in Leishmaniasis. *Clin Microbiol Rev* 19:111–126. <https://doi.org/10.1128/CMR.19.1.111-126.2006>.
- Steverding D. 2017. The history of leishmaniasis. *Parasit Vectors* 10:82. <https://doi.org/10.1186/s13071-017-2028-5>.
- De Luca PM, Macedo A. 2016. Cutaneous leishmaniasis vaccination: a matter of quality. *Front Immunol* 7:151–151. <https://doi.org/10.3389/fimmu.2016.00151>.
- da Silva Santos C, Brodsky CI. 2014. The role of CD4 and CD8 T cells in human cutaneous leishmaniasis. *Front Public Health* 2:165. <https://doi.org/10.3389/fpubh.2014.00165>.
- Liu D, Uzonna JE. 2012. The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response. *Front Cell Infect Microbiol* 2:83–83. <https://doi.org/10.3389/fcimb.2012.00083>.
- Garnier T, Croft SL. 2002. Topical treatment for cutaneous leishmaniasis. *Curr Opin Invest Drugs* 3:538–544.
- Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. 2004. Treatment of cutaneous leishmaniasis among travellers. *J Antimicrob Chemother* 53: 158–166. <https://doi.org/10.1093/jac/dkh058>.
- Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL. 2018. Relation between skin pharmacokinetics and efficacy in AmBisome treatment of murine cutaneous leishmaniasis. *Antimicrob Agents Chemother* 62:e02009-17. <https://doi.org/10.1128/AAC.02009-17>.
- Yardley V, Croft SL. 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. *Antimicrob Agents Chemother* 41:752–756. <https://doi.org/10.1128/AAC.41.4.752>.
- WHO. 2010. Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. World Health Organization, Geneva, Switzerland. <http://apps.who.int/iris/handle/10665/44412>. Accessed 22–26 March.
- Wortmann G, Zapor M, Ressler R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A. 2010. Liposomal amphotericin B for treatment of cutaneous leishmaniasis. *Am J Trop Med Hyg* 83:1028–1033. <https://doi.org/10.4269/ajtmh.2010.10-0171>.
- Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A. 2017. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). *Am J Trop Med Hyg* 96:24–45. <https://doi.org/10.4269/ajtmh.16-84256>.
- Tiunan TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV. 2011. Recent advances in leishmaniasis treatment. *Int J Infect Dis* 15: e525–e532. <https://doi.org/10.1016/j.ijid.2011.03.021>.
- Gonzalez U, Pinart M, Reveiz L, Alvar J. 2008. Interventions for Old World cutaneous leishmaniasis. *Cochrane Database Syst Rev* 2008:CD005067. <https://doi.org/10.1002/14651858.CD005067.pub3>.
- Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. *Cochrane Database Syst Rev* 2009:CD004834. <https://doi.org/10.1002/14651858.CD004834.pub2>.
- Cheung RC, Ng TB, Wong JH, Chan WY. 2015. Chitosan: an update on potential biomedical and pharmaceutical applications. *Mar Drugs* 13: 5156–5186. <https://doi.org/10.3390/md13085156>.
- Goy RC, Britto D, Assis OBG. 2009. A review of the antimicrobial activity of chitosan. *Polimeros* 19:241–247. <https://doi.org/10.1590/S0104-14282009000300013>.
- Hadwiger LA, Kendra DF, Fristensky BW, Wagoner W. 1986. Chitosan both activates genes in plants and inhibits RNA synthesis in fungi, p 209–214. *In* Muzzarelli R, Jeuniaux C, Gooday GW (ed), *Chitin in nature and technology*. Springer US, Boston, MA.
- Sarkar K, Xue Y, Sant S. 2017. Host response to synthetic versus natural biomaterials, p 81–105. *In* Corradetti B (ed), *The immune response to implanted materials and devices: the impact of the immune system on the success of an implant*. Springer International Publishing, Cham, Switzerland.
- Porporatto C, Bianco ID, Riera CM, Correa SG. 2003. Chitosan induces different L-arginine metabolic pathways in resting and inflammatory macrophages. *Biochem Biophys Res Commun* 304:266–272. [https://doi.org/10.1016/s0006-291x\(03\)00579-5](https://doi.org/10.1016/s0006-291x(03)00579-5).
- Ravindranathan S, Koppolu BP, Smith SG, Zaharoff DA. 2016. Effect of chitosan properties on immunoreactivity. *Mar Drugs* 14:E91. <https://doi.org/10.3390/md14050091>.
- Wu N, Wen ZS, Xiang XW, Huang YN, Gao Y, Qu YL. 2015. Immunostimulative activity of low molecular weight chitosans in RAW264.7 macrophages. *Mar Drugs* 13:6210–6225. <https://doi.org/10.3390/md13106210>.
- Peluso G, Pettillo O, Ranieri M, Santini M, Ambrosio L, Calabró D, Avallone B, Balsamo G. 1994. Chitosan-mediated stimulation of macrophage function. *Biomaterials* 15:1215–1220. [https://doi.org/10.1016/0142-9612\(94\)90272-0](https://doi.org/10.1016/0142-9612(94)90272-0).
- Dai T, Tanaka M, Huang Y-Y, Hamblin MR. 2011. Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. *Expert Rev Anti Infect Ther* 9:857–879. <https://doi.org/10.1586/eri.11.59>.
- Fu X, Shen Y, Jiang X, Huang D, Yan Y. 2011. Chitosan derivatives with dual-antibacterial functional groups for antimicrobial finishing of cotton fabrics. *Carbohydr Polym* 85:221–227. <https://doi.org/10.1016/j.carbpol.2011.02.019>.
- Tiera MJ, Qiu XP, Bechaouch S, Shi Q, Fernandes JC, Winnik FM. 2006. Synthesis and characterization of phosphorylcholine-substituted chitosans soluble in physiological pH conditions. *Biomacromolecules* 7:3151–3156. <https://doi.org/10.1021/bm060381u>.
- Pujals G, Suñé-Negre JM, Pérez P, García E, Portus M, Tico JR, Miñarro M, Carrió J. 2008. In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. *Parasitol Res* 102:1243–1247. <https://doi.org/10.1007/s00436-008-0901-z>.
- Ribeiro TG, Chávez-Fumagalli MA, Valadares DG, França JR, Rodrigues LB, Duarte MC, Lage PS, Andrade PHR, Lage DP, Arruda LV, Abánades DR, Costa LE, Martins VT, Tavares CAP, Castilho RO, Coelho EAF, Faraco A. 2014. Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system. *Int J Nanomedicine* 9:877–890. <https://doi.org/10.2147/IJN.S55678>.
- Salah-Tazdait R, Tazdait D, Harrat Z, Eddaikra N, Abdi N, Mameri N. 2015. Antiparasite activity of chitosan, p 277–280. *Proceedings of 2015 International Conference on Chemical, Metallurgy and Environmental Engineering, Istanbul, Turkey, 3 to 4 June 2015*. <https://pdfs.semanticscholar.org/23d6/0270c0cdb5c0dbd05e8c977c2f0f01e35fcb.pdf>.
- Bahrami S, Esmaeilzadeh S, Zarei M, Ahmadi F. 2015. Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major. *Parasitol Res* 114:4617–4624. <https://doi.org/10.1007/s00436-015-4707-5>.
- Hoseini MH, Moradi M, Alimohammadian MH, Shahgoli VK, Darabi H, Rostami A. 2016. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection. *Parasitol Int* 65: 99–104. <https://doi.org/10.1016/j.parint.2015.10.007>.
- Asthana S, Jaiswal AK, Gupta PK, Pawar VK, Dube A, Chourasia MK. 2013. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. *Antimicrob Agents Chemother* 57:1714–1722. <https://doi.org/10.1128/AAC.01984-12>.
- McAdams TA, Miller WM, Papoutsakis ET. 1997. Variations in culture pH affect the cloning efficiency and differentiation of progenitor cells in ex vivo haemopoiesis. *Br J Haematol* 97:889–895. <https://doi.org/10.1046/j.1365-2141.1997.1372951.x>.
- Fernandes ACS, Soares DC, Saraiva EM, Meyer-Fernandes JR, Souto-Padrón T. 2013. Different secreted phosphatase activities in Leishmania amazonensis. *FEMS Microbiol Lett* 340:117–128. <https://doi.org/10.1111/1574-6968.12080>.
- Xu W, Xin L, Soong L, Zhang K. 2011. Sphingolipid degradation by Leishmania major is required for its resistance to acidic pH in the

- mammalian host. *Infect Immun* 79:3377–3387. <https://doi.org/10.1128/IAI.00037-11>.
38. Gupta G, Oghumu S, Satoskar AR. 2013. Mechanisms of immune evasion in leishmaniasis. *Adv Appl Microbiol* 82:155–184. <https://doi.org/10.1016/B978-0-12-407679-2.00005-3>.
 39. Scott P, Novais FO. 2016. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. *Nat Rev Immunol* 16:581–592. <https://doi.org/10.1038/nri.2016.72>.
 40. Balicka-Ramis A, Wojtasz-Pajak A, Pilarczyk B, Ramisz A, Laurans L. 2005. Antibacterial and antifungal activity of chitosan, p 406–408. Proceedings of the XIIIth International Congress in Animal Hygiene, vol 2. Bel Studio, Warsaw, Poland.
 41. Shanmugam A, Kathiresan K, Nayak L. 2015. Preparation, characterization and antibacterial activity of chitosan and phosphorylated chitosan from cuttlebone of *Sepia kobeensis* (Hoyle, 1885). *Biotechnol Rep (Amsterdam, Netherlands)* 9:25–30. <https://doi.org/10.1016/j.btre.2015.10.007>.
 42. Kean T, Thanou M. 2010. Biodegradation, biodistribution and toxicity of chitosan. *Adv Drug Deliv Rev* 62:3–11. <https://doi.org/10.1016/j.addr.2009.09.004>.
 43. Richardson SC, Kolbe HV, Duncan R. 1999. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. *Int J Pharm* 178: 231–243. [https://doi.org/10.1016/S0378-5173\(98\)00378-0](https://doi.org/10.1016/S0378-5173(98)00378-0).
 44. Ardila N, Daigle F, Heuzey MC, Aji A. 2017. Effect of chitosan physical form on its antibacterial activity against pathogenic bacteria. *J Food Sci* 82:679–686. <https://doi.org/10.1111/1750-3841.13635>.
 45. Tsai GJ, Su WH. 1999. Antibacterial activity of shrimp chitosan against *Escherichia coli*. *J Food Prot* 62:239–243. <https://doi.org/10.4315/0362-028x-62.3.239>.
 46. Sahariah P, Masson M. 2017. Antimicrobial chitosan and chitosan derivatives: a review of the structure-activity relationship. *Biomacromolecules* 18:3846–3868. <https://doi.org/10.1021/acs.biomac.7b01058>.
 47. Seyfarth F, Schliemann S, Elsner P, Hipler UC. 2008. Antifungal effect of high- and low-molecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-D-glucosamine against *Candida albicans*, *Candida krusei* and *Candida glabrata*. *Int J Pharm* 353:139–148. <https://doi.org/10.1016/j.ijpharm.2007.11.029>.
 48. Qiu M, Wu C, Ren G, Liang X, Wang X, Huang J. 2014. Effect of chitosan and its derivatives as antifungal and preservative agents on postharvest green asparagus. *Food Chem* 155:105–111. <https://doi.org/10.1016/j.foodchem.2014.01.026>.
 49. Jeon Y-J, Park P-J, Kim S-K. 2001. Antimicrobial effect of chitoooligosaccharides produced by bioreactor. *Carbohydr Polym* 44:71–76. [https://doi.org/10.1016/S0144-8617\(00\)00200-9](https://doi.org/10.1016/S0144-8617(00)00200-9).
 50. Seifert K, Escobar P, Croft SL. 2010. In vitro activity of anti-leishmanial drugs against *Leishmania donovani* is host cell dependent. *J Antimicrob Chemother* 65:508–511. <https://doi.org/10.1093/jac/dkp500>.
 51. Green SJ, Scheller LF, Marletta MA, Seguin MC, Klotz FW, Slayter M, Nelson BJ, Nacy CA. 1994. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. *Immunol Lett* 43:87–94. [https://doi.org/10.1016/0165-2478\(94\)00158-8](https://doi.org/10.1016/0165-2478(94)00158-8).
 52. Tokura S, Tamura H, Azuma I. 1999. Immunological aspects of chitin and chitin derivatives administered to animals. *EXS* 87:279–292. https://doi.org/10.1007/978-3-0348-8757-1_20.
 53. Salehi F, Behboudi H, Kavooosi G, Ardestani SK. 2017. Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA. *RSC Adv* 7:43141–43150. <https://doi.org/10.1039/C7RA06793C>.
 54. Li H, Shi B, Yan S, Zhao T, Li J, Guo X. 2014. Effects of chitosan on the secretion of cytokines and expression of inducible nitric oxide synthase mRNA in peritoneal macrophages of broiler chicken. *Braz Arch Biol Technol* 57:466–471. <https://doi.org/10.1590/S1516-8913201401903>.
 55. Smith AC, Yardley V, Rhodes J, Croft SL. 2000. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. *Antimicrob Agents Chemother* 44:1494–1498. <https://doi.org/10.1128/aac.44.6.1494-1498.2000>.
 56. Soldati T, Schliwa M. 2006. Powering membrane traffic in endocytosis and recycling. *Nat Rev Mol Cell Biol* 7:897–908. <https://doi.org/10.1038/nrm2060>.
 57. Hoemann CD, Guzmán-Morales J, Tran-Khanh N, Lavallée G, Jolicoeur M, Lavertu M. 2013. Chitosan rate of uptake in HEK293 cells is influenced by soluble versus microparticle state and enhanced by serum-induced cell metabolism and lactate-based media acidification. *Molecules* 18: 1015–1035. <https://doi.org/10.3390/molecules18011015>.
 58. Fong D, Gregoire-Gelinas P, Cheng AP, Mezheritsky T, Lavertu M, Sato S, Hoemann CD. 2017. Lysosomal rupture induced by structurally distinct chitosans either promotes a type 1 IFN response or activates the inflammasome in macrophages. *Biomaterials* 129:127–138. <https://doi.org/10.1016/j.biomaterials.2017.03.022>.
 59. Szczepanska J, Pawlowska E, Synowiec E, Czarny P, Rekas M, Blasiak J, Szaflik JP. 2011. Protective effect of chitosan oligosaccharide lactate against DNA double-strand breaks induced by a model methacrylate dental adhesive. *Med Sci Monit* 17:BR201–BR208. <https://doi.org/10.12659/msm.881898>.
 60. Abrica-González P, Zamora-Justo JA, Sotelo-López A, Vázquez-Martínez GR, Balderas-López JA, Muñoz-Diosdado A, Ibáñez-Hernández M. 2019. Gold nanoparticles with chitosan, N-acylated chitosan, and chitosan oligosaccharide as DNA carriers. *Nanoscale Res Lett* 14:258. <https://doi.org/10.1186/s11671-019-3083-y>.
 61. Tzaneva D, Simitchiev A, Petkova N, Nenov V, Stoyanova A, Denev P. 2017. Synthesis of carboxymethyl chitosan and its rheological behaviour in pharmaceutical and cosmetic emulsions. *J Appl Pharm Sci* 7:070–078.
 62. Barros LM, Duarte AE, Morais-Braga MF, Waczuk EP, Vega C, Leite NF, de Menezes IR, Coutinho HD, Rocha JB, Kamdem JP. 2016. Chemical characterization and trypanocidal, leishmanicidal and cytotoxicity potential of *Lantana camara* L. (Verbenaceae) essential oil. *Molecules* 21:209. <https://doi.org/10.3390/molecules21020209>.
 63. Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL. 2017. Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis. *Antimicrob Agents Chemother* 61:e00358-17. <https://doi.org/10.1128/AAC.00358-17>.
 64. Zhao Y-L, Tian P-X, Han F, Zheng J, Xia X-X, Xue W-J, Ding X-M, Ding C-G. 2017. Comparison of the characteristics of macrophages derived from murine spleen, peritoneal cavity, and bone marrow. *J Zhejiang Univ Sci B* 18:1055–1063. <https://doi.org/10.1631/jzus.B1700003>.
 65. Chang KP. 1980. Endocytosis of *Leishmania*-infected macrophages. In *Fluorometry of pinocytotic rate, lysosome-phagosome fusion and intralysosomal pH*, p 231–234. Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands.
 66. Antoine JC, Prina E, Jouanne C, Bongrand P. 1990. Parasitophorous vacuoles of *Leishmania amazonensis*-infected macrophages maintain an acidic pH. *Infect Immun* 58:779–787. <https://doi.org/10.1128/IAI.58.3.779-787.1990>.
 67. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR. 2007. Tamoxifen is effective against *Leishmania* and induces a rapid alkalization of parasitophorous vacuoles harbouring *Leishmania (Leishmania) amazonensis* amastigotes. *J Antimicrob Chemother* 60: 526–534. <https://doi.org/10.1093/jac/dkm219>.
 68. Foresi N, Correa-Aragunde N, Amenta M, Arruebarrena A, Creus C, Lamattina L. 2016. Detection of nitric oxide and determination of nitrite concentrations in *Arabidopsis thaliana* and *Azospirillum brasilense*. *Bio Protoc* 6:e1765. <https://doi.org/10.21769/BioProtoc.1765>.
 69. Dutta D, Donaldson JG. 2012. Search for inhibitors of endocytosis: intended specificity and unintended consequences. *Cell Logist* 2:203–208. <https://doi.org/10.4161/cl.23967>.
 70. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, Chang J, Combs CA, Malide D, Zhang WY. 2005. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. *J Biol Chem* 280:2352–2360. <https://doi.org/10.1074/jbc.M407167200>.
 71. Michael DP, Ashlin TG, Davies CS, Gallagher H, Stoneman TW, Buckley ML, Ramji DR. 2013. Differential regulation of macropinocytosis in macrophages by cytokines: implications for foam cell formation and atherosclerosis. *Cytokine* 64:357–361. <https://doi.org/10.1016/j.cyto.2013.05.016>.
 72. O’Keefe A, Hyndman L, McGinty S, Riezk A, Murdan S, Croft SL. 2019. Development of an in vitro media perfusion model of *Leishmania* major macrophage infection. *PLoS One* 14:e0219985. <https://doi.org/10.1371/journal.pone.0219985>.
 73. Jaskolski F, Mülle C, Manzoni OJ. 2005. An automated method to quantify and visualize colocalized fluorescent signals. *J Neurosci Methods* 146:42–49. <https://doi.org/10.1016/j.jneumeth.2005.01.012>.
 74. Valiante S, Falanga A, Cigliano L, Iachetta G, Busiello RA, La Marca V, Galdiero M, Lombardi A, Galdiero S. 2015. Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats. *Int J Nanomedicine* 10:1885–1898. <https://doi.org/10.2147/IJN.S77734>.